Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma

NCT05618925 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Non Hodgkin's Lymphoma Refractory/Relapsed

Interventions

DRUG: N803
BIOLOGICAL: CD19t-haNK suspension
DRUG: Cyclophosphamide
DRUG: Fludarabine
DRUG: Rituximab

Sponsor

ImmunityBio, Inc.